Oral Huzhang Granules for Acute Gouty Arthritis

• Status: Not yet recruiting
• Trial end date: 2023-08-31
• Target enrollment: 0
• Participant gender: All

Summary

We designed this study as a double-blind, randomized, controlled clinical trial. The aim of the study is to evaluate the clinical efficacy, safety and control of recurrence rate of acute gouty arthritis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Yueyang Integrated Medicine Hospital
• Treatments: Etoricoxib

Criteria

Inclusion Criteria:

• Diagnosis of acute gout arthritis as defined by the American College of Rheumatology 1977 preliminary criteria;

• Male or non-pregnant, non-nursing female;

• 18-70 years of age;

• Gout attack less ≤48 hours;

• In the week before this observation, non-steroidal anti-inflammatory drugs and analgesic drugs and drugs affecting uric acid metabolism were not taken;

• Subjects capable of giving informed consent;

Exclusion Criteria:

• failing to meet the diagnostic criteria;

• Evidence of uncontrolled concomitant cardiovascular, nervous system,hepatic or gastrointestinal disease. Potential participants who have active concomitant disease can only be eligible after discussion and agreement with the treating medical team;

• the patient is in critical condition and it is difficult to evaluate the effectiveness and safety of the clinical observation;

• severe deformity, stiffness and labor loss of patients with advanced arthritis;

• known allergic to the drug used in this study.